Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare BATS:ARKGNYSEARCA:ARKKNASDAQ:EXAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARKGARK Genomic Revolution ETF$21.93-7.1%$22.05$17.51▼$31.16$1.38B1.82.75 million shs4.90 million shsARKKARK Innovation ETF$50.84-1.3%$49.19$36.85▼$68.43$5.49B1.989.26 million shs11.52 million shsEXASExact Sciences$45.64+1.9%$45.07$39.97▼$72.83$8.48B1.142.60 million shs2.08 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARKGARK Genomic Revolution ETF-0.49%+4.53%+3.54%-15.17%-6.71%ARKKARK Innovation ETF+0.57%+11.73%+5.81%-16.70%+14.21%EXASExact Sciences-1.75%+1.45%+2.59%-18.40%-23.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AN/AN/AN/AN/AN/AEXASExact Sciences4.3984 of 5 stars4.52.00.04.72.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARKGARK Genomic Revolution ETF 2.74Moderate Buy$21.93N/AARKKARK Innovation ETF 2.58Moderate Buy$50.84N/AEXASExact Sciences 2.95Moderate Buy$69.2551.73% UpsideCurrent Analyst Ratings BreakdownLatest EXAS, ARKK, and ARKG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025EXASExact SciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/10/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$65.00 ➝ $55.004/10/2025EXASExact SciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.004/9/2025EXASExact SciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/28/2025EXASExact SciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.003/13/2025EXASExact SciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$52.002/26/2025EXASExact SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.002/24/2025EXASExact SciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$70.00 ➝ $73.002/20/2025EXASExact SciencesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/20/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$70.00 ➝ $65.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AN/AN/AN/AEXASExact Sciences$2.76B3.07$5.19 per share8.79$12.93 per share3.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARKGARK Genomic Revolution ETFN/AN/A0.00∞N/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/A29.14∞N/AN/AN/AN/AN/AEXASExact Sciences-$204.15M-$5.57N/A91.28N/A-37.29%-5.29%-2.45%5/1/2025 (Estimated)Latest EXAS, ARKK, and ARKG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025EXASExact Sciences-$0.35N/AN/AN/A$688.58 millionN/A2/19/2025Q4 2024EXASExact Sciences-$0.29-$0.06+$0.23-$4.67$701.45 million$713.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AARKKARK Innovation ETFN/A0.00%N/AN/AN/AEXASExact SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARKGARK Genomic Revolution ETFN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AEXASExact Sciences0.972.151.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARKGARK Genomic Revolution ETFN/AARKKARK Innovation ETFN/AEXASExact Sciences88.82%Insider OwnershipCompanyInsider OwnershipARKGARK Genomic Revolution ETFN/AARKKARK Innovation ETFN/AEXASExact Sciences1.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARKGARK Genomic Revolution ETFN/A45.45 millionN/ANot OptionableARKKARK Innovation ETFN/A108.05 millionN/ANot OptionableEXASExact Sciences6,400185.76 million182.56 millionOptionableEXAS, ARKK, and ARKG HeadlinesRecent News About These CompaniesExact Sciences (EXAS) Reports Q1: Everything You Need To Know Ahead Of EarningsApril 30 at 9:47 PM | finance.yahoo.comThese 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarApril 30 at 9:50 AM | zacks.comExact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025April 29 at 9:46 PM | finance.yahoo.comSusquehanna Fundamental Investments LLC Takes $12.66 Million Position in Exact Sciences Co. (NASDAQ:EXAS)April 29 at 6:16 AM | marketbeat.comAdage Capital Partners GP L.L.C. Buys Shares of 378,200 Exact Sciences Co. (NASDAQ:EXAS)April 29 at 5:39 AM | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Shares Bought by Hsbc Holdings PLCApril 29 at 5:06 AM | marketbeat.comTower Research Capital LLC TRC Purchases 11,745 Shares of Exact Sciences Co. (NASDAQ:EXAS)April 29 at 4:46 AM | marketbeat.comPrice T Rowe Associates Inc. MD Grows Stake in Exact Sciences Co. (NASDAQ:EXAS)April 28 at 5:17 AM | marketbeat.comNebula Research & Development LLC Invests $3.28 Million in Exact Sciences Co. (NASDAQ:EXAS)April 27 at 6:57 AM | marketbeat.comThis Exact Sciences Insider Increased Their Holding In The Last YearApril 26, 2025 | finance.yahoo.com13,520 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Syon Capital LLCApril 26, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Has $239.92 Million Position in Exact Sciences Co. (NASDAQ:EXAS)April 26, 2025 | marketbeat.comFirst Trust Advisors LP Decreases Stock Position in Exact Sciences Co. (NASDAQ:EXAS)April 26, 2025 | marketbeat.com101,173 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Marshall Wace LLPApril 26, 2025 | marketbeat.comExact Sciences (EXAS) Projected to Post Earnings on ThursdayApril 26, 2025 | marketbeat.comLeerink Partnrs Predicts Weaker Earnings for Exact SciencesApril 25, 2025 | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Position Increased by BI Asset Management Fondsmaeglerselskab A SApril 25, 2025 | marketbeat.com2 Reasons to Like EXAS (and 1 Not So Much)April 24, 2025 | finance.yahoo.comExact Sciences (EXAS): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside PotentialApril 24, 2025 | finance.yahoo.comExact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseApril 24, 2025 | zacks.comLeerink Partnrs Forecasts Higher Earnings for Exact SciencesApril 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonTop 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldBy Thomas Hughes | April 14, 2025View Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryBy Jeffrey Neal Johnson | April 27, 2025View Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryEXAS, ARKK, and ARKG Company DescriptionsARK Genomic Revolution ETF BATS:ARKG$21.89 -1.72 (-7.27%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.ARK Innovation ETF NYSEARCA:ARKK$50.84 -0.69 (-1.34%) As of 04:10 PM EasternThe ARK Innovation ETF (ARKK) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that seeks long-term capital growth from companies globally involved with, or that benefit from, disruptive innovation. ARKK was launched on Oct 31, 2014 and is managed by ARK.Exact Sciences NASDAQ:EXAS$45.64 +0.85 (+1.90%) As of 04:00 PM EasternExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
